Significant weight gain with rezulin therapy.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Archives of Internal Medicine

• Publication date

  1999-01-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHINTE.159.1.99PMID 9892338
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

  1998cited by this paper

• Control of lower extremity edema in patients with diabetes: Double blind randomized controlled trial assessing the efficacy of mild compression diabetic socks.

  2017cites this paper
• Oral and Injectable (Non-insulin) Pharmacological Agents for Type 2 Diabetes

  2016cites this paper
• Insulin Resistance, Metabolic Syndrome, and Therapy

  2012cites this paper
• Pharmacogenetics of Anti-Diabetes Drugs

  2010cites this paper
• Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARγ agonist pioglitazone

  2008cites this paper
• MRI assessment of drug-induced fluid accumulation in humans: validation of the technology.

  2008cites this paper
• Pharmacotherapy of Diabetes

  2007cites this paper
• The Glitazones, Lessons so Far

  2007cites this paper
• PPARγ agonists: safety issues in heart failure

  2007cites this paper
• Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.

  2007cites this paper
• PPAR-γ Ligands and Diabetic Nephropathy

  2006cites this paper
• Do thiazolidinediones cause heart failure? A critical review.

  2006cites this paper
• Chapter 24 – Insulin-Sensitizing and Insulin-Sparing Drugs: Thiazolidinediones and Metformin

  2006cites this paper
• Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents

  2005cites this paper
• Combined Thiazolidinedione-Insulin Therapy

  2004cites this paper
• The Addition of Rosiglitazone Is Effective in Patients with Type 2 Diabetes Poorly Controlled with Oral Hypoglycemic Agents

  2004cites this paper
• Ischemic heart disease and congestive heart failure in diabetic patients.

  2004cites this paper
• PPARγ activation enhances cell surface ENaCα via up‐regulation of SGK1 in human collecting duct cells

  2003cites this paper
• Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability

  2003cites this paper
• Weight Effect of Current and Experimental Drugs for Diabetes Mellitus

  2003cites this paper
• Effects of a PPAR&ggr; Agonist, GI262570, on Renal Filtration Fraction and Nitric Oxide Level in Conscious Rats

  2003cites this paper
• Possible Heart Failure Exacerbation Associated with Rosiglitazone: Case Report and Literature Review

  2003cites this paper
• PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells.

  2003cites this paper
• Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.

  2003cites this paper
• Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

  2003cites this paper
• The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.

  2003cites this paper
• PPAR(gamma) and glucose homeostasis.

  2003cites this paper
• Drug‐induce cardiac failure

  2003cites this paper
• Role of the Adipocyte in Type 2 Diabetes

  2003cites this paper
• Peripheral edema.

  2002cites this paper
• Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.

  2002cites this paper
• Thiazolidinediones: A Review of Their Benefits and Risks

  2002cites this paper
• Comment: Drug—Herb Interaction

  2001cites this paper
• Cardiomyopathy and heart failure in diabetes.

  2001cites this paper
• Pulmonary Edema Associated with Rosiglitazone and Troglitazone

  2001cites this paper
• Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.

  2001cites this paper
• Deterioration of rheumatoid arthritis with troglitazone: a rare and unexpected adverse effect.

  2000cites this paper
• Nonhypoglycemic drug reactions of agents used to treat diabetes.

  2000cites this paper
• The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.

  2000cites this paper
• Practical Issues in the Treatment of Patients with Heart Failure

  2000cites this paper
• Pulmonary edema associated with troglitazone therapy.

  1999cites this paper
• Review Article Peroxisome Proliferator-activated Receptors in Diabetic Nephropathy

  year unknowncites this paper